Included in the formulation
АТХ:J.05.A.X.05 Inosin pranobeks
Pharmacodynamics:It binds to the ribosomes of virus-infected cells, disrupting the processes of transcription and translation, which leads to a slowdown in the synthesis of viral RNA and inhibits the replication of RNA and DNA genomic viruses.
It induces the formation of interferon. Activates the synthesis of cytokines and increases the phagocytic activity of macrophages. Enhances and accelerates the proliferation of T and B lymphocytes.
Active against influenza A and B, Herpes simplex, cytomegalovirus and measles virus, polioviruses, human type T-cell lymphoma virus, ECHO virus (enterocytopathogenic human virus), encephalomyocarditis and equine encephalitis.
Pharmacokinetics:After oral administration, the empty stomach is completely absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 1 hour. Do not cumulate.
The therapeutic effect develops 30 minutes after the beginning of the intake and lasts for 6 hours. Metabolism in the liver with the formation of uric acid.
The half-life is 50 minutes, the complete excretion of inosine and metabolites is completed after 48 hours. Elimination by the kidneys in the form of metabolites.
Indications:It is used to treat diseases of viral etiology: influenza, parainfluenza, adenovirus and rhinovirus infections, measles, mumps.
It is used for diseases caused by herpes simplex viruses, Varicella zoster (shingles, chicken pox), with infectious mononucleosis (Epstein-Barr virus), cytomegalovirus infection, human papillomavirus, acute and chronic viral hepatitis B, and also in patients with weakened immunity in chronic recurrent infections of the genitourinary (chlamydia) and respiratory system .
I.A50-A64.A60 Anogenital herpetic viral infection [herpes simplex]
I.A80-A89.A81.1 Subacute sclerosing panencephalitis
XVI.P35-P39.P35.2 Congenital infection caused by the herpes simplex virus [herpes simplex]
I.B00-B09.B01 Chicken Pox [varicella]
I.B00-B09.B02 Shingles [herpes zoster]
I.B00-B09.B05 Measles
I.B00-B09.B07 Viral Warts
I.B00-B09.B08.1 Molluscum contagiosum
I.B25-B34.B25 Cytomegalovirus
I.B25-B34.B27 Infectious mononucleosis
I.B95-B97.B97.7 Papillomaviruses as a cause of diseases classified elsewhere
X.J10-J18.J10 Influenza caused by an identified influenza virus
Contraindications:Gout, arrhythmia, urolithiasis, chronic renal failure, individual intolerance, children under 2 years old.
Carefully:Acute renal failure, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - category is not defined. Contraindicated in pregnancy and lactation.
Dosing and Administration:Use in children
Inside, from 2 to 12 years: 50 mg / kg per day in 3-4 hours.
Adults
Adults and children over 12 years: from 500 mg to 4 g / kg per day in 3-4 doses.
The highest daily dose: 4 g.
The highest single dose: 500 mg.
For patients with immunosuppression, the course of treatment is from 3 to 9 weeks.
Side effects:Central and peripheral nervous system: dizziness, headache, fatigue, drowsiness or insomnia.
Digestive system: decreased appetite, nausea, pain in epigastrium, rarely - diarrhea, constipation.
Musculoskeletal system: arthralgia.
Urinal system: polyuria.
Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:Immunosuppressants weaken the effect of inosine pranobeksa.
Increases concentration and prolongs the half-life of zidovudine when used simultaneously.
Enhances the effects of α-interferon and acyclovir.
Special instructions:Control of uric acid in serum and urine.
In the treatment it is not recommended to drive vehicles and work with moving mechanisms.